COPD Clinical Trials Near You

COPD clinical trials in 2026 are moving beyond bronchodilator combinations toward disease-modifying therapies targeting the underlying inflammatory and destructive processes. Biologic therapies, proven in asthma, are finally showing promise for specific COPD phenotypes: dupilumab demonstrated a 30% reduction in exacerbations in type 2 high (eosinophilic) COPD patients, while anti-IL-33 (itepekimab, tozorakimab) and anti-TSLP antibodies target upstream inflammatory pathways.

Triple inhaler therapy (ICS/LAMA/LABA) in single devices is established, but trials are testing whether adding a phosphodiesterase-3/4 inhibitor (ensifentrine, a novel dual PDE3/PDE4 nebulized bronchodilator) as a fourth agent provides additional benefit for severe COPD.

Alpha-1 antitrypsin (AAT) augmentation therapy trials explore new delivery methods and dosing for the genetic form of emphysema, while gene therapy approaches aim to provide long-term AAT production from a single treatment.

Lung volume reduction procedures — both surgical and bronchoscopic (endobronchial valves, coils) — are in comparative trials to determine which patients with hyperinflated emphysema benefit most. Regenerative medicine trials test whether stem cells or growth factors can stimulate alveolar repair.

Patient considerations: COPD trials require documented airflow limitation on spirometry (FEV1/FVC ratio) and often classify patients by GOLD stage and exacerbation history. Expect regular lung function tests, 6-minute walk tests, and symptom questionnaires (CAT, mMRC). Many trials require a recent exacerbation history (1–2 in the past year) for enrollment. Smoking cessation may be required, and carbon monoxide testing verifies abstinence.